Palmitoylethanolamide is now regarded by experts in the field as as a disease-modifying agent in neuropathic pain. This is very special, as none of the current analgesics have disease modifying properties, none of all are neuro-protectants. But palmitoylethanolamide (PeaPure, een PEA-houdend product) is!
Dr S. Skraper, one of the leading PEA researchers in the world and a pupil of the Nobel laureate Rita Levi-Montalcini published a paper on PEA bearing the title:
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain
In the paper Skraper and colleagues analysed all literature around PEA and its clinical value and concluded:
The discovery that palmitoylethanolamide, a member of the N-acylethanolamine family which is produced from the lipid bilayer on-demand, is capable of exerting anti-allodynic and anti-hyperalgesic effects by down-modulating both microglial and mast cell activity has led to the application of this fatty acid amide in several clinical studies of neuropathic pain, with beneficial outcome and no indication of adverse effects at pharmacological doses. Collectively, the findings presented here propose that palmitoylethanolamide merits further consideration as a disease-modifying agent for controlling inflammatory responses and related chronic and neuropathic pain.
Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2013 Nov 1. [Epub ahead of print]